Bayer women's health pipeline
Bayer is the lead sponsor of 5 active trials in the conditions TrialsForHer tracks (Menopause), 2 of them open to recruitment now or about to open.
Trials
Open trials first, then by primary completion date. Phases: Phase 3: 2, Phase 1: 2, Observational: 1. "est." marks the sponsor's estimated date; CTIS search results don't include primary completion dates. Registry sponsor names grouped here: Bayer; Bayer AG; Bayer Consumer Care AG, Bayer AG.
| ID | Title | Condition | Lead sponsor | Phase | Status | Primary completion | Enrolment | Site countries |
|---|---|---|---|---|---|---|---|---|
| NCT07762287 ClinicalTrials.gov | Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants | Menopause | Bayer | Phase 1 | Recruiting | 22 Feb 2027 (est.) | 100 | Canada |
| NCT07490431 ClinicalTrials.gov | An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States | Menopause | Bayer | Observational | Not yet recruiting | 30 Nov 2029 (est.) | 2,400 | — |
| NCT05587296 ClinicalTrials.gov | A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer | Menopause | Bayer | Phase 3 | Active, not recruiting | 29 Jan 2024 | 474 | Austria, Belgium, Canada, Finland +12 |
| 2023-508265-33-00 EU CTIS | A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks and optionally for additional up to 3.5 years in women with, or at high risk for developing hormone-receptor positive breast cancer | Menopause | Bayer Consumer Care AG, Bayer AG | Phase 3 | Ongoing, recruitment ended | — | — | Austria, Belgium, Finland, France +8 |
| 2026-525569-30-00 EU CTIS | A study to learn how a high-fat meal affects the way elinzanetant is taken up by the body in healthy women | Menopause | Bayer AG | Phase 1 | Ongoing, recruitment ended | — | — | Germany |
See also: upcoming women's-health trial readouts · Endometriosis trials · PCOS trials · Menopause trials
Track women's-health pipelines every Monday
New trials, phase changes, stopped trials and new sponsors across the conditions we track, with registry links.
Your ticks help us prioritise what to build. They don't commit you to anything, and no payment is taken.